Industries > Pharma > Pharmaceutical Contract Manufacturing Market 2017-2027

Pharmaceutical Contract Manufacturing Market 2017-2027

Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

PUBLISHED: 02 February 2017
PAGES: 235
PRODUCT CODE: PHA0167

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0167 Categories: , ,

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.4% in the first half of the forecast period and CAGR of 5.7% in the second half of the forecast period. The market is estimated at $88bn in 2021 and $124bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 235-page report you will receive 82 tables and 61 figures– all unavailable elsewhere.

The 235-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Pharmaceutical Contract Manufacturing Market 2017-2027

Report Scope
Global Pharmaceutical Contract Manufacturing Market forecasts from 2017-2027

Submarket forecasts at world level, from 2017-2027:
Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
Other applications of outsourced production – other related services

Revenue forecasts from 2017-2027, for 12 countries:
– United States (US)
– EU5: Germany, France, the UK, Italy and Spain
– BRIC: Brazil, Russia, India and China
– South Korea
– Japan

• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

Qualitative Analysis from a CMO Perspective 2016-2027

Qualitative Analysis from a Client Perspective 2016-2027

Visiongain’s study is intended for anyone requiring commercial analyses for the Pharmaceutical Contract Manufacturing Market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2017-2027: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2017-2027


Latest Pharma news

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

READ

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

READ

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

READ